All patients who enrolled on the trial and received treatment with SM-88 were given wearable devices to passively capture biometric data. Of these patients, 16 were synchronized on cycle 1 day 1, 20 had available data that was synchronized within the first 2 weeks, and 1 patient did not have the technical support available to collect information. Read more . . .
Step counts appeared to correlate with self-reported quality of life during the first 2 weeks of treatment with SM-88 in patients with metastatic pancreatic cancer, the results of a preliminary exploratory analysis from part 2 of the phase 2/3 TYME-88-Panc trial showed.